Phylogica, an Australian drug discovery company, has extended its research collaboration and licensing agreement with Genentech to discover novel antibiotics.
Mylan has entered into a sub-licensing agreement with the Medicines Patent Pool, a UN-backed public health organisation, to expand access to chronic hepatitis C medicines in developing countries.
Pharmaceutical company Sanofi and its subsidiary Genzyme have recovered a domain name that infringed a trademark at the World Intellectual Property Organization’s Arbitration and Mediation Center.
Healthcare company Novartis has won a domain name dispute at the World Intellectual Property Organization Arbitration and Mediation Center.
AstraZeneca and Cilag, an affiliate of Johnson & Johnson, have entered into an agreement for AstraZeneca to divest the rights to Rhinocort Aqua outside the US.
Teva and Regeneron Pharmaceuticals have combined to develop and commercialise fasinumab, a novel nerve growth factor (NGF) antibody.
More than 2,000 medicine brands treating common conditions will drop in price for millions of Australians from October 1, according to the Australian government’s Department of Health.
Eli Lilly has won a cybersquatting case in which the company successfully ordered the transfer of more than 200 domain names that purported to offer discounted erectile dysfunction drugs.
Roche has defeated a cybersquatter in a dispute centring on 18 domain names that infringed trademarks owned by the pharmaceutical company.
A new fund dedicated to accelerate the development and commercialisation of Australian biomedical discoveries has officially launched.